000			01588 a2200457 4500
005			20250514064210.0
264		0	_c20030509
008			200305s 0 0 eng d
022			_a1468-201X
024	7		_a10.1136/heart.89.5.535 _2doi
040			_aNLM _beng _cNLM
100	1		_aBrown, D L
245	0	0	_aDeaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. _h[electronic resource]
260			_bHeart (British Cardiac Society) _cMay 2003
300			_a535-7 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAbciximab
650	0	4	_aAdult
650	0	4	_aAdverse Drug Reaction Reporting Systems
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngioplasty, Balloon, Coronary
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aDeath, Sudden _xetiology
650	0	4	_aEptifibatide
650	0	4	_aFemale
650	0	4	_aHemorrhage _xchemically induced
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyocardial Ischemia _xdrug therapy
650	0	4	_aPeptides _xadverse effects
650	0	4	_aPlatelet Aggregation Inhibitors _xadverse effects
650	0	4	_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors
650	0	4	_aRisk Factors
650	0	4	_aTirofiban
650	0	4	_aTyrosine _xadverse effects
773	0		_tHeart (British Cardiac Society) _gvol. 89 _gno. 5 _gp. 535-7
856	4	0	_uhttps://doi.org/10.1136/heart.89.5.535 _zAvailable from publisher's website
999			_c12487223 _d12487223